Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer

Moderate hypofractionation for prostate cancer

At the end of the last century, Brenner and Hall [1] argued that the fractionation sensitivity of prostate cancer was different from most tumors and normal tissues, with the opportunity to increase the therapeutic ratio by treating this cancer with hypofractionation (fewer, larger daily fractions). Nearly two decades later, the use of moderate hypofractionation for prostate cancer has become an...

Hypofractionation trials and radiobiology of prostate cancer

Prostate cancer and hypofractionation: really a new standard of care?

The Lancet Oncology published in June 2016 results of the CHHiP trial (1): a randomized phase 3, non-inferiority trial testing a standard radiotherapy treatment for localized prostate cancer (74 Gy in 37 fractions over 7.4 weeks) compare to two more protracted schedules: 60 Gy in 20 fractions/4 weeks or 57 Gy in 19 fractions/3.8 weeks. The majority of enrolled patients had low or intermediate-r...

The role of radiotherapy in node-positive prostate cancer.

Node-positive prostate cancer represents 12% of newly diagnosed prostate cancer cases in the United States; with decreasing use of screening, this proportion is likely to increase. However, very few clinical trials have specifically compared treatment options for this group of patients. Radiotherapy has a potential role as both definitive therapy and adjuvant therapy for node-positive prostate ...

Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliance

External beam radiation therapy with conventional fractionation to a total dose of 76-80 Gy represents the most adopted treatment modality for prostate cancer. Dose escalation in this setting has been demonstrated to improve biochemical control with acceptable toxicity using contemporary radiotherapy techniques. Hypofractionated radiotherapy and stereotactic body radiation therapy have gained a...